Hostname: page-component-78c5997874-94fs2 Total loading time: 0 Render date: 2024-11-16T06:41:04.629Z Has data issue: false hasContentIssue false

Can Fecal Microbiota Transplantation (FMT) Eradicate Fecal Colonization With Vancomycin-Resistant Enterococci (VRE)?

Published online by Cambridge University Press:  03 October 2016

Kyung Mok Sohn*
Affiliation:
Division of Infectious Diseases, Chungnam National University Hospital, Chungnam National University School of Medicine, Daejeon, South Korea.
Shinhye Cheon
Affiliation:
Division of Infectious Diseases, Chungnam National University Hospital, Chungnam National University School of Medicine, Daejeon, South Korea.
Yeon-Sook Kim
Affiliation:
Division of Infectious Diseases, Chungnam National University Hospital, Chungnam National University School of Medicine, Daejeon, South Korea.
*
Address correspondence to Kyung Mok Sohn, MD, Division of Infectious Diseases, Chungnam National University Hospital, Chungnam National University School of Medicine, 282 Munhwa-ro, Jung-gu, Daejeon 35015, Republic of Korea ([email protected]).
Rights & Permissions [Opens in a new window]

Abstract

Type
Letters to the Editor
Copyright
© 2016 by The Society for Healthcare Epidemiology of America. All rights reserved 

To the Editor—Recently, fecal microbiota transplantation (FMT) has been attempted to eliminate colonization with multidrug-resistant organisms (MDROs), and case reports have shown considerable success.Reference Young and Hayden 1 In addition, FMT was effective for reducing antibiotic resistant genes in patients with recurrent Clostridium difficile infection (CDI),Reference Millan, Park and Hotte 2 which may have a significant role in MDRO decolonization. However, publication bias could exist against studies with negative findings for MDRO decolonization, and clinical evidence for extending the application of FMT remains sparse. We performed FMT to eradicate long-term vancomycin-resistant enterococci (VRE) colonization in 3 patients. Prolonged VRE colonization was documented by repeated rectal swab cultures (positive VRE on at least 4 consecutive swabs taken 1 week apart). Of these 3 patients, 2 had recurrent CDI and were treated with oral metronidazole and vancomycin (Table 1, cases 1 and 2). Another patient (case 3) remained in the hospital for isolation purposes due to VRE carriage after completion of treatment. Vancomycin resistance was confirmed using chromogenic agar and polymerase chain reaction. All cases were Enterococcus faecium with the vanA gene. Voluntary informed consent was obtained for FMT. Stools were donated by the patient’s granddaughter (case 1, 18 years old), daughter (case 2, 45 years old), and son (case 3, 50 years old), respectively. The donors were healthy and no problems were identified on pre-donation screening tests; they were all negative for stool VRE. Oral vancomycin treatment was discontinued on the day before FMT (case 1 and 2), and the donor stool (100 g) in normal saline (200 mL) was transplanted to the patient via retention enema after environmental disinfection. All patients were able to retain the infusate for at least 1 hour, and there were no adverse events. In case 3, a second FMT was performed 1 day after the first FMT. All antibiotics were stopped after the FMT was conducted except in case 2, in which the patient developed pneumonia 15 days after FMT and piperacillin-tazobactam was given for 2 weeks. Patient characteristics and outcomes are summarized in Table 1. Patients 1 and 2 experienced resolution of CDI symptoms without recurrence during admission. After transferring to other facilities, 2 patients were lost to follow-up. We did not recruit additional patients because FMT did not shorten the duration of VRE carriage in these 3 patients.

TABLE 1 Clinical Characteristics and Outcomes of Patients with Vancomycin-Resistant Enterococci Colonization Who Underwent Fecal Microbiota Transplantation

NOTE. FMT, fecal microbiota transplantation; CDI, Clostridium difficile infection; HTN, hypertension; DM, diabetes mellitus; RA, rheumatoid arthritis; VRE, vancomycin-resistant enterococci.

a Patient 1 was discharged from the hospital 1 month after FMT. She cleared VRE colonization 15 weeks after FMT (3 consecutive negative VRE cultures a minimum of 1 week apart at the outpatient clinic).

b Patent 2 was transferred to a long-term care facility 10 weeks after FMT and was lost to follow-up.

c Patient 2 developed pneumonia 15 days after FMT, and piperacillin-tazobactam was given for 2 weeks.

d Patient 3 was transferred to a long-term care facility 21 weeks after FMT and no further rectal VRE cultures were performed.

Our data are supported by the Jang et alReference Jang, An, Jung and Park 3 case report in which FMT was performed twice to control refractory CDI. Their patient was also colonized with VRE and, despite resolution of CDI, rectal VRE carriage persisted for at least 3 months. Although we used the lower delivery route (enema), Jang et al transplanted stool via both enema and the upper route (nasoduodenal tube).Reference Jang, An, Jung and Park 3

Ubeda et alReference Ubeda, Bucci and Caballero 4 showed that reintroduction of a diverse intestinal microbiota to heavily VRE-colonized mice could eliminate VRE from the gut. Specifically, the presence of Barnesiella species in the intestinal tract was able to confer resistance to VRE in patients undergoing allogeneic hematopoietic stem cell transplantation.Reference Ubeda, Bucci and Caballero 4 Stielfel et alReference Stiefel, Nerandzic, Pultz and Donskey 5 reported that cephalosporinase-producing Bacteroides thetaiotaomicron prevented overgrowth of VRE and C. difficile in cephalosporin-treated mice. Defined microbiota transplant instead of whole stool may lead to more successful outcomes. Although these data are promising, it is not clear whether single bacterial species transfers would work in the human gastrointestinal tract.

In an industry-sponsored trial using an experimental microbiota suspension, 8 of 11 patients (73%) became VRE negative 1–6 months following FMT by enema.Reference Dubberke and Jones 6 However, the patients could have experienced spontaneous eradication. Because clearance of VRE varies widely, occurring after a median time of <3 months after discharge from the hospital without FMT and 6.5 months after antibiotics that promote VRE are discontinued,Reference Sohn, Peck and Joo 7 , Reference Shenoy, Paras, Noubary, Walensky and Hooper 8 it remains unclear whether FMT reduces the duration of VRE colonization.

Although FMT may contribute to shrinkage of the gut resistome, it does not seem to effectively shorten the duration of VRE carriage and may not be justified for the clearance of fecal colonization with VRE. Ongoing clinical trials will help resolve this issue and should help identify more effective methods of FMT against VRE colonization.

ACKNOWLEDGMENTS

Financial support. No financial support was provided relevant to this article.

Potential conflicts of interest. All authors report no conflicts of interest relevant to this article.

References

REFERENCES

1. Young, VB, Hayden, MK. Environmental management in the gut: fecal transplantation to restore the intestinal ecosystem. Infect Dis (Lond) 2016;48:593595.CrossRefGoogle ScholarPubMed
2. Millan, B, Park, H, Hotte, N, et al. Fecal microbial transplants reduce antibiotic-resistant genes in patients with recurrent Clostridium difficile infection. Clin Infect Dis 2016;62:14791486.Google Scholar
3. Jang, MO, An, JH, Jung, SI, Park, KH. Refractory Clostridium difficile infection cured with fecal microbiota transplantation in vancomycin-resistant Enterococcus colonized patient. Intest Res 2015;13:8084.Google Scholar
4. Ubeda, C, Bucci, V, Caballero, S, et al. Intestinal microbiota containing Barnesiella species cures vancomycin-resistant Enterococcus faecium colonization. Infect Immun 2013;81:965973.CrossRefGoogle ScholarPubMed
5. Stiefel, U, Nerandzic, MM, Pultz, MJ, Donskey, CJ. Gastrointestinal colonization with a cephalosporinase-producing Bacteroides species preserves colonization resistance against vancomycin-resistant Enterococcus and Clostridium difficile in cephalosporin-treated mice. Antimicrob Agents Chemother 2014;58:45354542.Google Scholar
6. Dubberke, E, Jones, C. Clearance of vancomycin-resistant Enterococcus concomitant with administration of a microbiota-based drug targeted at recurrent Clostridium difficile infection. In: 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25–28 2015. Copenhagen, Denmark: Poster 0912.Google Scholar
7. Sohn, KM, Peck, KR, Joo, EJ, et al. Duration of colonization and risk factors for prolonged carriage of vancomycin-resistant enterococci after discharge from the hospital. Int J Infect Dis 2013;17:e240e246.CrossRefGoogle ScholarPubMed
8. Shenoy, ES, Paras, ML, Noubary, F, Walensky, RP, Hooper, DC. Natural history of colonization with methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE): a systematic review. BMC Infectious Dis 2014;14:177.Google Scholar
Figure 0

TABLE 1 Clinical Characteristics and Outcomes of Patients with Vancomycin-Resistant Enterococci Colonization Who Underwent Fecal Microbiota Transplantation